If it’s the one from the CHORD study, it’s this one.
“DB-OTO, which is a cell-selective, adeno-associated virus (AAV) gene therapy product candidate”
Basically, they give them an injection in the cochlea of a modified virus that doesn’t cause disease and only infects specific cells, which then invades those cells, delivering a payload of the gene they want to insert. The new DNA gets put in the nucleus so the cell can manufacture the new protein to allow hearing.
This only works with people who have that mutation as the cause for their deafness.
If it’s the one from the CHORD study, it’s this one.
“DB-OTO, which is a cell-selective, adeno-associated virus (AAV) gene therapy product candidate”
Basically, they give them an injection in the cochlea of a modified virus that doesn’t cause disease and only infects specific cells, which then invades those cells, delivering a payload of the gene they want to insert. The new DNA gets put in the nucleus so the cell can manufacture the new protein to allow hearing.
This only works with people who have that mutation as the cause for their deafness.